Welcome to our dedicated page for Aeluma SEC filings (Ticker: ALMU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aeluma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aeluma's regulatory disclosures and financial reporting.
Paglia John Kenneth reported acquisition or exercise transactions in this Form 4 filing.
Aeluma, Inc. director John Kenneth Paglia reported receiving a grant of 10,861 shares of common stock in the form of restricted stock units at a stated price of $0 per share. Following this award, he holds 23,361 shares directly. The units are scheduled to vest over time: about 1/12 on December 31, 2025, 1/4 each on March 31, June 30, and September 30, 2026, and 1/6 on November 30, 2026.
Aeluma, Inc. director Byron Michael reported receiving equity-based compensation in the form of common stock and stock options. He was granted 13,343 shares of common stock as restricted stock units that are scheduled to vest over several dates through November 30, 2026. The vesting schedule covers approximately 1/12 of the shares on December 31, 2025, 1/4 of the shares on March 31, June 30, and September 30, 2026, and 1/6 of the shares on November 30, 2026. He also acquired stock options for 3,653 shares that are fully vested as of the grant, giving him the right to buy additional common stock.
Denbaars Steven reported acquisition or exercise transactions in this Form 4 filing.
Aeluma, Inc. director Steven Denbaars reported an equity award of 10,121 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share. Following this grant, his reported direct holdings total 395,209 shares of common stock.
The restricted stock units are scheduled to vest over several dates: approximately one-twelfth of the shares on December 31, 2025, one-quarter of the shares on March 31, June 30, and September 30, 2026, and the remaining one-sixth on November 30, 2026.
Aeluma, Inc. director Steven Denbaars reported selling a total of 25,000 shares of common stock in two open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 20, 2025. He sold 12,500 shares on February 25, 2026 at a weighted average price of $17.5813 per share and 12,500 shares on February 26, 2026 at a weighted average price of $15.8475 per share, with actual sale prices on each day spanning disclosed ranges. After these sales, he continues to hold 385,088 shares directly.
Aeluma, Inc. (ALMU) received an updated large‑holder report from investor Mark N. Tompkins, disclosing a significant passive stake in the company. He reports beneficial ownership of 2,024,988 shares of Aeluma common stock, representing 11.34% of the outstanding shares as of December 31, 2025.
The percentage is based on 17,857,863 Aeluma common shares outstanding as of November 21, 2025, as cited from the company’s proxy statement. Tompkins has sole voting and sole dispositive power over all reported shares and certifies the holdings are not for the purpose of changing or influencing control of Aeluma.
Aeluma, Inc. reported revenue of $2.7 million for the six months ended December 31, 2025, up from $2.1 million a year earlier, mainly from U.S. government contracts. Operating expenses rose sharply to $6.3 million, driven by higher materials costs and expanding headcount, leading to a net loss of $3.3 million, slightly better than the prior period’s $3.6 million loss.
The company strengthened its balance sheet with two underwritten equity offerings in March and September 2025, providing net proceeds of $12.6 million and $23.4 million. Cash, cash equivalents and a certificate of deposit increased to $38.6 million, and management states that prior substantial doubt about its ability to continue as a going concern has been alleviated for at least the next twelve months. However, disclosure controls and procedures were deemed not effective due to limited finance staffing, and remediation efforts, including hiring a new chief financial officer and adding accounting resources, are underway.
Aeluma, Inc. reported financial results for its second quarter of fiscal 2026, for the period ended December 31, 2025. Revenue for the quarter was $1.27 million, compared with $1.39 million in the prior quarter and $1.61 million a year earlier, while the company posted a GAAP net loss of $1.85 million (or $0.11 per share).
For the first six months of fiscal 2026, revenue totaled $2.66 million and the GAAP net loss was $3.35 million. On a non-GAAP basis, which excludes stock-based compensation, certain financing-related items, and other adjustments, Aeluma reported a second-quarter net loss of $0.80 million and adjusted EBITDA of $(0.92) million.
The company emphasized progress toward commercialization, citing increasing customer engagements and initial sales orders, and reaffirmed its full fiscal 2026 revenue outlook in the range of $4.0 million to $6.0 million. Aeluma ended the quarter with $38.57 million in cash and cash equivalents, supporting ongoing research, development, and go-to-market activities.
Aeluma, Inc. is registering up to 14,011,726 shares of common stock for resale by existing selling stockholders. The shares come from prior private offerings, a merger conversion, pre‑merger holders and convertible notes, plus shares issuable on placement agent warrants.
Aeluma will not receive proceeds from stockholder resales, but may receive cash if the warrants are exercised. Its common stock trades on Nasdaq under the symbol ALMU. The company qualifies as an emerging growth and smaller reporting company, using scaled disclosure requirements.